Jun 15, 2026 12:00PM
Jun 11, 2026 07:00AM
Jun 11, 2026 07:00AM
Jun 9, 2026 04:30PM
Jun 9, 2026 04:30PM
May 13, 2026 05:46AM
May 13, 2026 02:38AM Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
May 4, 2026 08:00AM
May 4, 2026 08:00AM
Mar 30, 2026 04:21AM
Mar 28, 2026 03:00PM
Mar 2, 2026 06:01AM
Mar 2, 2026 02:00AM
Feb 19, 2026 12:00PM Takeda reports positive pediatric trial results for ENTYVIO ulcerative colitis treatment
Feb 19, 2026 12:00PM
Feb 10, 2026 04:50AM
Feb 10, 2026 03:15AM
Jan 29, 2026 01:37AM
Jan 22, 2026 07:45AM
Jan 22, 2026 07:45AM
Jan 14, 2026 09:00AM Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Jan 5, 2026 07:03AM
Jan 5, 2026 07:00AM
Dec 18, 2025 03:00AM
Dec 18, 2025 03:00AM
Dec 8, 2025 02:54AM
Dec 6, 2025 09:30AM
Nov 7, 2025 11:01AM Takeda reports sustained kidney function benefits 18 months after treatment
Nov 7, 2025 11:00AM
Nov 3, 2025 08:33AM
Nov 3, 2025 07:00AM
Oct 30, 2025 03:04AM
Oct 27, 2025 08:35AM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
Sep 23, 2025 06:04PM
Sep 16, 2025 08:02AM
Sep 16, 2025 08:00AM
Sep 11, 2025 08:45AM
Sep 11, 2025 08:45AM
Sep 8, 2025 03:00AM
Sep 8, 2025 03:00AM Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
Sep 5, 2025 08:45PM
Sep 5, 2025 08:45PM
Jul 30, 2025 02:41AM
Jul 21, 2025 08:01AM
Jul 21, 2025 08:00AM
Jul 14, 2025 05:55AM
Jul 14, 2025 03:00AM Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Jun 30, 2025 08:00AM

1,160,116 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All